Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Inhibrx Biosciences, Inc
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Emory University
Emory University
University of California, San Diego
Sanford Health
National Cancer Institute (NCI)
University of Leipzig
Celldex Therapeutics